Cytokinetics Presents New Data In Patients With Non-Obstructive HCM From Cohort 4 Of REDWOOD-HCM In Late-Breaking Clinical Trial Session At The European Society Of Cardiology Heart Failure 2023 Congress
Portfolio Pulse from Benzinga Newsdesk
Cytokinetics (NASDAQ:CYTK) presented new data from Cohort 4 of REDWOOD-HCM, a Phase 2 clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The treatment showed statistically significant improvements in various health measures, and a Phase 3 clinical trial is set to begin in 2H 2023.
May 20, 2023 | 7:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cytokinetics' aficamten demonstrated significant improvements in nHCM patients during the Phase 2 trial, with a Phase 3 trial set to begin in 2H 2023.
The positive results from the Phase 2 trial of aficamten in nHCM patients indicate potential for the drug's success in the upcoming Phase 3 trial. This could lead to increased investor interest and a positive short-term impact on Cytokinetics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100